About Sichuan Kelun Pharmaceutical Company

The company was founded in 1996 and has now formed a “product” structure operation platform composed of Colon Pharmaceutical, Twining Biotech, and Colun Botai. In 2017, Colon ranked 155th in China's top 500 manufacturing companies. In 2018, Colon was awarded the “Single Champion Demonstration Enterprise in the Manufacturing Industry” for its global advantages in high-volume injections. In 2022, Colon ranked among the top three in China's pharmaceutical manufacturing industry. It is mainly engaged in R&D, production and sales of 24 dosage forms of drugs, such as high-volume injections (infusions), small-volume injections (including dispensed powder needles and freeze-dried powder needles), tablets, capsules, granules, oral solutions, peritoneal dialysis solutions, APIs, etc., as well as antibiotic intermediates, medical devices, etc. The main products cover anti-tumor, cardiovascular, anesthetic and analgesic, psychiatric, anti-pathogenic microorganisms, nutritional infusions, respiratory, anti-osteoporosis, male specialty, diabetes, hydroelectrolyte balance, diagnostic imaging, hepatitis B and other diseases. Corporate honors: National Technological Innovation Demonstration Enterprise, Industrial Brand Cultivation Demonstration Enterprise, National Science and Technology Progress Award, etc.